Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy

Autor: Takahiro Osawa, Hideki Uchino, Gaku Mouri, Satoshi Chiba, Shintaro Maru, Ataru Sazawa
Rok vydání: 2018
Předmět:
Male
Time Factors
Peptide Hormones
medicine.medical_treatment
Cancer Treatment
030232 urology & nephrology
lcsh:Medicine
Biochemistry
Metastasis
Gonadotropin-Releasing Hormone
Androgen deprivation therapy
Prostate cancer
0302 clinical medicine
Basic Cancer Research
Medicine and Health Sciences
Reproductive System Procedures
lcsh:Science
Multidisciplinary
Pharmaceutics
Prostatectomy
Prostate Cancer
Prostate Diseases
Prognosis
Radical Prostatectomy
Prostate-specific antigen
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Androgens
Hormonal therapy
Luteinizing hormone
Research Article
medicine.medical_specialty
Drug Administration
Antineoplastic Agents
Hormonal
medicine.drug_class
Urology
Surgical and Invasive Medical Procedures
03 medical and health sciences
Drug Therapy
Diagnostic Medicine
medicine
Humans
Aged
Retrospective Studies
Surgical Excision
business.industry
lcsh:R
Prostatic Neoplasms
Biology and Life Sciences
Cancers and Neoplasms
Luteinizing Hormone
medicine.disease
Androgen
Survival Analysis
Hormones
Genitourinary Tract Tumors
lcsh:Q
Neoplasm Recurrence
Local
business
Zdroj: PLoS ONE, Vol 13, Iss 5, p e0197252 (2018)
PLoS ONE
ISSN: 1932-6203
Popis: Purpose Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outcomes of patients with prostate-specific antigen recurrence who underwent radical prostatectomy at our department. Materials and methods Of the 690 patients who underwent radical prostatectomy for local prostate cancer between 1988 and 2011, 129 patients who received androgen deprivation therapy for prostate-specific antigen recurrence were included in this study. Patient characteristics, luteinizing hormone-releasing hormone agonist administration, and outcomes were compared between the intermittent androgen deprivation group (n = 66) and the continuous androgen deprivation therapy group (n = 63). The non-recurrence and overall survival rates were compared between groups. Results Thirty-six patients (27.9%) experienced recurrence after luteinizing hormone-releasing hormone agonist administration. The 5-year non-recurrence rate and 10-year overall survival rate were higher in the intermittent group (92.9%) than in the continuous group (92.9 vs 57.9%, P < 0.001; and 95.9% vs 84.3%, P = 0.047, respectively). Furthermore, 63 patients (48.8%) showed a PSA nadir of less than 0.01 ng/mL after initiation of luteinizing hormone-releasing hormone agonist; among these patients, the non-recurrence rate was significantly higher in the intermittent androgen deprivation group (P = 0.003). Conclusions Intermittent androgen deprivation therapy for prostate specific antigen recurrence after radical prostatectomy contributed to improvement of the non-recurrence rate and overall survival, and can be considered an effective therapy for better prognosis.
Databáze: OpenAIRE
Externí odkaz: